Showing results (911-920 of 1,842) with videos related to

Sort By:
Pageof 185
ESMO Open|August 2, 2017
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
ESMO Open|August 2, 2017
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancerFloriana Morgillo, Morena Fasano, Carminia Maria Della Corte, et al.
ESMO Open|August 2, 2017
The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective studyXing-Fei Yu, Chen Wang, Bo Chen, et al.
ESMO Open|August 2, 2017
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancerAtsuko Kitano, Makiko Ono, Masayuki Yoshida, et al.
ESMO Open|August 2, 2017
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)Michele Orditura, Adriano Gravina, Ferdinando Riccardi, et al.
ESMO Open|October 12, 2017
Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinomaJian Lu, Jin-He Guo, Hai-Dong Zhu, et al.
ESMO Open|October 12, 2017
The care of adolescents and young adults with cancer: results of the ESMO/SIOPE surveyEmmanouil Saloustros, Daniel P Stark, Kyriaki Michailidou, et al.
ESMO Open|June 27, 2018
Empirical antimicrobial treatment in haemato-/oncological patients with neutropenic sepsisMatthias Gerhard Vossen, Christopher Milacek, Florian Thalhammer
ESMO Open|October 13, 2017
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patientsAnastassia Negrouk, Denis Lacombe, Fatima Cardoso, et al.
ESMO Open|September 27, 2019
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancerClaudia Cardone, Erika Martinelli, Teresa Troiani, et al.
Pageof 185